Research Article Details
| Article ID: | A46516 |
| PMID: | 18068003 |
| Source: | Arch Med Res |
| Title: | Influence of insulin resistance and adipocytokines on elevated serum alanine aminotransferase in obese patients. |
| Abstract: | BACKGROUND: Insulin resistance and adipocytokines have been associated with fatty liver and nonalcoholic fatty liver disease. The aim of our study was to study the influence of insulin resistance and adipocytokines in obese patients on elevated serum alanine aminotransferase (ALT). METHODS: A population of 214 female obese patients was studied cross-sectionally. HOMA-IR was calculated as indicator of insulin resistance. Adipocytokines (leptin, resistin, adiponectin, interleukin-6, and TNF-alpha) blood levels were measured. RESULTS: The mean age and body mass index of our study group was 38.2+/-14.7 years and 35.27+/-6.5, respectively. HOMA and leptin levels were higher in the third ALT tertile than in the first ALT tertile. Adiponectin level was higher in the first tertile than in the second and third tertiles. These parameters show statistical differences between the second and third ALT tertiles. In the multiple regresion analysis with a dependent variable (ALT) and the statistical univariant variables as independent variables, the HOMA-IR remained in the model with an increase of 0.27 U/L of ALT (CI 95%, 0.6-3.4) (F=8.1; p<0.05) with each 1 unit of HOMA-IR adjusted by age, weight, and dietary intake. CONCLUSIONS: Some metabolic parameters are associated with elevated ALT in obese female patients. However, adjusted by other variables, only insulin resistance remained associated. |
| DOI: | 10.1016/j.arcmed.2007.06.009 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |